SLDB
Solid Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.52
+3.82%Nov 4, 2026, 21:07 UTC
Solid Biosciences Inc. reported its third-quarter 2026 financial results and business updates, including that SGT-003 had been generally well tolerated in 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial as of November 3, 2026.
Source:Oct 26, 2026, 12:00 UTC
The European Commission granted orphan designation to Solid Biosciences' SGT-212 for the treatment of Friedreich's ataxia.
Source:Oct 20, 2026, 12:00 UTC
Solid Biosciences announced that seven abstracts were accepted for poster presentation at the ESGCT 2026 Annual Congress, scheduled for October 27–30 in Hamburg, Germany.
Source: